Father and baby son Lilly

Media Releases

View the latest media releases and news stories from Lilly Australia and New Zealand.

Lilly named a finalist in two categories at the Australian HR Awards

15 June 2021- Eli Lilly Australia & New Zealand has been shortlisted as an Excellence Awardee in two categories at the prestigious annual Australian HR Awards.

View Media Release

Lilly Unleashes the Power of Generational Diversity

9 June 2021-The Generation Diversity, Inclusion and Equity Group at Eli Lilly Australia & New Zealand (Lilly ANZ) aims to embrace and celebrate generational diversity to ensure employees from all generations feel their experiences, perspectives and ideas are valued.

View Media Release

Lilly Ranks No. 3 for the Second Year in DiversityInc's Top 50

18 May 2021- For the second year in a row, Lilly has been ranked third in DiversityInc’s list of Top 50Companies for Diversity. DiversityInc Top 50 list is issued annually and recognises top companies for diversity and inclusion management.

View Media Release

Lilly Appoints New Chief Marketing Officer

1 May 2021- Gabbi Mittas has been appointed as Chief Marketing Officer for Lilly's North Asia Pacific Hub (NAPAC), which includes Australia, New Zealand, Korea, Taiwan and Hong Kong.

View Media Release

TRULICITY® (dulaglutide) in combination with insulin is now available on the PBS for Australians with type 2 diabetes

1 March 2021- Eli Lilly Australia is pleased to announce that dulaglutide (TRULICITY®) is now reimbursed under the Pharmaceutical Benefits Scheme (PBS) for concomitant use with insulin for patients with type 2 diabetes (T2D).

View Media Release

Lilly ANZ Appoints Jill Schein as Incoming Senior HR Director

10 February 2021- Jill Schein has been appointed as Incoming Senior HR Director for Lilly’s North Asia Pacific Hub (NAPAC), which includes Australia, New Zealand, Korea, Taiwan, and Hong Kong.

View Media Release

TRULICITY® (dulaglutide) is now indicated in adults with type 2 diabetes to reduce the risk of Major Adverse Cardiovascular Events (MACE) in patients with multiple risk factors for, or established, cardiovascular disease.

12 August 2020 - Eli Lilly Australia welcomes the Therapeutic Goods Administration’s (TGA) acceptance of the expanded label indication for TRULICITY® (dulaglutide).

View Media Release

PP-MG-AU-0121 06/2021